Decreased circulating levels of von Willebrand factor after intravenous administration of a rapidly degradable hydroxyethyl starch (HES 200/0.5/6) in healthy human subjects
- First Online:
- Cite this article as:
- de Jonge, E., Levi, M., Büller, H. et al. Intensive Care Med (2001) 27: 1825. doi:10.1007/s001340101107
- 85 Downloads
Objective: Impairment of haemostasis has been described with slowly degradable medium molecular weight hydroxyethyl starch (MMW-HES), whereas rapidly degradable MMW-HES is generally considered to have no important effects on blood coagulation. This study was undertaken to investigate the effects of a rapidly degradable MMW-HES plasma substitute on primary haemostasis and blood coagulation in human subjects. Design: Randomised, cross-over study. Setting: Research unit of a university hospital. Participants: Nine healthy, adult male volunteers. Interventions: A 60-min intravenous infusion of 1 l HES 200/0.5/6 (HAES-steril 6%) or 4% albumin (control). Measurement and results: The infusion of HES resulted in decreased circulating levels of von Willebrand factor antigen (from 85±8% to 59±6% after HES vs from 80±7% to 69±8% after albumin, p<0.05) and ristocetin cofactor activity (from 93±4 to 67±4% after HES vs from 79±5 to 75±5% after albumin, p<0.01). This was associated with an impairment of in vitro platelet function as determined with the PFA-100 platelet function analyser (closure time with collagen/epinephrine from 120±7 to 159±14 s after HES vs from 121±7 to 137±10 s after albumin, p<0.05; with collagen/ADP from 88±3 to 116±9 s and from 103±4 to 114±7 s after HES and albumin, respectively, p=0.01). Conclusions: The infusion of 1 l of HES 200/0.5/6 in healthy human subjects results in moderately decreased plasma levels of von Willebrand factor associated with impairment of platelet function.